19-epi-Scholaricine

19-epi-Scholaricine 是一种具有口服活性的吲哚生物碱,可下调促纤维化/凋亡 (apoptosis) 蛋白 (HRAS, HSP90AA1, KDR) 的表达并上调细胞周期相关蛋白 (CDK2) 的表达,通过抑制 AKT/mTOR 进而抑制 ROS 生成、减少炎症介质释放,从而减轻足细胞凋亡、肾脏炎症和氧化应激,可用于慢性肾小球肾炎和膜性肾病研究。
产品编号: MS-X26400 纯度: 99.14% CAS No.: 132923-06-9 分子式: C20H24N2O4 分子量: 356.42
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价

产品描述

19-epi-Scholaricine 是一种具有口服活性的吲哚生物碱,可下调促纤维化/凋亡 (apoptosis) 蛋白 (HRAS, HSP90AA1, KDR) 的表达并上调细胞周期相关蛋白 (CDK2) 的表达,通过抑制 AKT/mTOR 进而抑制 ROS 生成、减少炎症介质释放,从而减轻足细胞凋亡、肾脏炎症和氧化应激,可用于慢性肾小球肾炎和膜性肾病研究。

生物实验数据

生物活性 19-epi-Scholaricine is an orally active indole alkaloid that downregulates the expression of pro-fibrotic/apoptosis proteins (HRAS, HSP90AA1, KDR) and upregulates the expression of the cell cycle-related protein (CDK2), and by inhibiting AKT/mTOR, it suppresses ROS generation and reduces the release of inflammatory mediators, thereby alleviating podocyte apoptosis, renal inflammation, and oxidative stress, making it applicable for research on chronic glomerulonephritis and membranous nephropathy.
体外研究
(In Vitro)

19-epi-Scholaricine (10-50 μM; 24 h) 可保护经 ADR 刺激的 MPC5 细胞免受损伤,在 50 μM 浓度处理 24 h 后能显著提高细胞存活率。
19-epi-Scholaricine (50 μM; 24 h) 可调节 ADR 诱导的 MPC5 细胞中 CGN 相关靶点的表达,下调 HRAS、HSP90AA1 和 KDR,同时上调 CDK2。
19-epi-Scholaricine (50 μM; 24 h) 可显著降低经 ADR 刺激的 MPC5 细胞内 ROS 生成水平。
19-epi-Scholaricine (1-20 μM; 25 h) 可抑制脂多糖 (LPS) (MS-X54539) 诱导的小鼠足细胞 MPC5 中 NO 的释放。
19-epi-Scholaricine (1 μM; 25 h) 可下调 LPS 诱导的小鼠足细胞系 MPC5 中 Tnf-α 和 Il-6 的基因表达。
19-epi-Scholaricine (1 μM; 25 h) 可上调 LPS 刺激的小鼠足细胞 MPC5 中的昼夜节律及 AKT/mTOR 通路基因表达。
19-epi-Scholaricine (1 μM; 24 h) 可降低 LPS 诱导的小鼠足细胞系 MPC5 中的活性氧 (ROS) 生成。
19-epi-Scholaricine (1 μM; 24 h) 可恢复经 LPS 刺激的小鼠足细胞 MPC5 的线粒体膜电位。

Cell Viability Assay

Cell Line: adriamycin (ADR)-stimulated murine glomerular podocyte (MPC5) cells
Concentration: 10, 20, 40 and 50 μM
Incubation Time: 24 h
Result: Increased the survival rate of ADR-stimulated MPC5 cells; the 50 μM concentration produced a statistically significant increase relative to the ADR-only model group.

Western Blot Analysis

Cell Line: adriamycin (ADR)-stimulated murine glomerular podocyte (MPC5) cells
Concentration: 50 μM
Incubation Time: 24 h
Result: Downregulated the protein expression of HRAS, HSP90AA1, and KDR, and upregulated the protein expression of CDK2 in ADR-stimulated MPC5 cells, reversing the expression changes induced by ADR.

Real Time qPCR

Cell Line: adriamycin (ADR)-stimulated murine glomerular podocyte (MPC5) cells
Concentration: 50 μM
Incubation Time: 24 h
Result: Downregulated the mRNA expression of hras, hsp90aa1, and kdr and upregulated the mRNA expression of cdk2 in ADR-stimulated MPC5 cells, reversing the expression changes induced by ADR.

Real Time qPCR

Cell Line: MPC5 murine podocytes (LPS-stimulated)
Concentration: 1 μM
Incubation Time: 1 h pre-incubation, then 24 h LPS stimulation
Result: Significantly reduced the LPS-induced expression of Tnf-α and IL-6 genes in MPC5 cells, restoring levels to near normal.\nUpregulated the expression of Arntl, Cry1, Akt, mTor, and Bcl-2/Bax genes in LPS-stimulated MPC5 cells.
体内研究
(In Vivo)

19-epi-Scholaricine (1 mg/kg;口服;每日一次;连续 28 天) 可通过降低尿蛋白水平、使血清肾功能生物标志物恢复正常及改善肾脏组织病理学表现,显著缓解阿霉素诱导的雄性 ICR 小鼠慢性肾小球肾炎。
19-epi-scholaricine (1.0 mg/kg;灌胃;每日;持续 6 周) 在膜性肾病小鼠模型中展现出优于或等同于 2 mg/kg 泼尼松的治疗效果,其依据为尿蛋白水平降低、肾功能恢复、炎症与氧化应激被抑制、组织病理学改善,以及对 ARNTL/AKT/mTOR 通路的调控作用。

Animal Model: ICR mice (male, 32-36 g, adriamycin-induced)
Dosage: 1 mg/kg
Administration: p.o.; daily; 28 days
Result: Reduced urinary protein levels from 11.51 mg/24 h (model group) to 8.84 mg/24 h at day 7.
Attenuated the ADR-induced decrease in serum albumin (ALB) from 30.74 U/L (model group) to 35.92 U/L, and in serum total protein (TP) from 51.01 U/L (model group) to 55.63 U/L.
Reduced serum urea nitrogen (BUN) levels from 9.49 μmol/L (model group) to 8.44 μmol/L.
Ameliorated kidney histopathological damage, including reduced diffuse proliferation of glomerular tracts and decreased lymphocyte/plasma cell infiltration.
Animal Model: ICR (male, 25 ± 3 g, membranous nephropathy induced by 5 mg/kg C-BSA tail vein injection every 3 days for 6 doses)
Dosage: 1.0 mg/kg
Administration: oral gavage; daily; 6 weeks
Result: Reduced 24-hour urinary protein from 9.9 to 6.2 mg.
Increased the urine creatinine (Ucr)/blood creatinine (Scr) ratio from 42.7 to 76.5.
Decreased renal C3 deposition integrated fluorescence signal from 2.1 to 0.52.
Reduced renal IL-1β expression from 4.4 to 1.4.
Normalized oxidative stress markers (malondialdehyde, glutathione, superoxide dismutase, catalase) in kidney homogenates.
Ameliorated histopathological renal lesions including lymphocyte infiltration, loosely stained cytoplasm, and glomerular basement membrane (GBM) thickening to near-normal levels.
Upregulated renal expression of circadian rhythm genes (Arntl, Cry1) and downregulated phosphorylated AKT/mTOR pathway components.
性状 固体
颜色 Light yellow to light brown

化学信息

分子量 356.42
分子式 C20H24N2O4
CAS No. 132923-06-9

储存&溶解度

储存方式

4°C, protect from light

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础